(19)
(11) EP 2 310 415 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
13.12.2017 Bulletin 2017/50

(45) Mention of the grant of the patent:
11.10.2017 Bulletin 2017/41

(21) Application number: 09734929.4

(22) Date of filing: 24.04.2009
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
G01N 33/68(2006.01)
(86) International application number:
PCT/US2009/002536
(87) International publication number:
WO 2009/131702 (29.10.2009 Gazette 2009/44)

(54)

ANTIBODIES AGAINST FCRN AND USE THEREOF

ANTIKÖRPER GEGEN FCRN UND DEREN VERWENDUNG

PROTÉINES DE LIAISON AU RÉCEPTEUR FC


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30) Priority: 25.04.2008 US 48152 P
28.04.2008 US 48500 P

(43) Date of publication of application:
20.04.2011 Bulletin 2011/16

(60) Divisional application:
17195757.4

(73) Proprietors:
  • Dyax Corp.
    Burlington, MA 01803 (US)
  • Biogen Hemophilia Inc.
    Waltham, MA 02451 (US)

(72) Inventors:
  • TENHOOR, Christopher
    Hopkinton MA 01748 (US)
  • MURUGANANDAM, Arumugam
    Bangalore 560035 (IN)
  • LADNER, Robert, Charles
    Ijamsville MD 21754 (US)
  • WOOD, Clive
    Boston, MA 02114 (US)
  • BITONTI, Alan, J.
    Acton MA 01720 (US)
  • STATTEL, James
    Hagerstown MD 21740 (US)
  • MCDONNELL, Kevin
    Waltham MA 02451 (US)
  • LIU, Liming
    Upper Dublin PA 19002 (US)
  • DUMONT, Jennifer
    Groton MA 01450 (US)
  • SATO, Aaron
    Richmond CA 94805 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A-2006/118772
US-A1- 2007 092 507
WO-A-2007/087289
   
  • LIU LIMING ET AL: "Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade" JOURNAL OF IMMUNOLOGY, vol. 178, no. 8, April 2007 (2007-04), pages 5390-5398, XP009124948 ISSN: 0022-1767
  • GETMAN KATE E ET AL: "Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions" JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 94, no. 4, 1 April 2005 (2005-04-01), pages 718-729, XP002417287 ISSN: 0022-3549
  • LI NING ET AL: "Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases" JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 12, December 2005 (2005-12), pages 3440-3450, XP009124853 ISSN: 0021-9738
  • AKILESH SHREERAM ET AL: "The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease" JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 9, 1 May 2004 (2004-05-01), pages 1328-1333, XP002417288 ISSN: 0021-9738
  • ROOPENIAN DERRY C ET AL: "FcRn: the neonatal Fc receptor comes of age" NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 7, no. 9, 1 September 2007 (2007-09-01), pages 715-725, XP002510057 ISSN: 1474-1733
  • LORIN ROSKOS ET AL: "Molecular Engineering II: Antibody Affinity", HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, no. Part I, Chapter 7, 30 March 2007 (2007-03-30), XP007912251, ISBN: 978-3-527-31453-9 [retrieved on 2008-02-01]
  • STEPHAN DUEBEL ED - STEFAN DÜBEL: "Handbook of Therapeutic Antibodies Chapter 6", 1 January 2007 (2007-01-01), HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, PAGE(S) 119 - 144, XP007913671, ISBN: 978-3-527-31453-9
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).